Key result
DAPT outperforms monotherapy for acute management and secondary prevention of non-cardioembolic ischemic stroke and TIA.
Why the study?
To provide an updated review discussing major clinical trials up until late 2023, areas of controversy, and recent developments in dual antiplatelet therapy for secondary stroke prevention.
Does dual antiplatelet therapy improve secondary stroke prevention in patients with non-cardioembolic stroke and transient ischemic attack compared to antiplatelet monotherapy?
Does dual antiplatelet therapy improve secondary stroke prevention in patients with non-cardioembolic stroke and transient ischemic attack compared to antiplatelet monotherapy?
This review provides an updated overview of dual antiplatelet therapy strategies for the acute management and long-term secondary prevention of ischemic stroke and TIA based on recent trials and guidelines.
Answers are grounded in this paper and cite their sources.
May support DAPT strategies in non-cardioembolic stroke/TIA; leaves open optimal duration and bleeding trade-offs for prospective trials.
To improve the efficacy over antiplatelet monotherapy, dual antiplatelet therapy (DAPT) has been increasingly adopted in the management of non-cardioembolic stroke. For minor ischemic stroke and high-risk transient ischemic attack, the aspirin-clopidogrel combination is now recommended for acute short-term treatment, whereas aspirin-ticagrelor combination may be considered in selected patients, especially those with resistance to clopidogrel. For long-term stroke prevention, aspirin-dipyridamole combination has been used as an alternative to antiplatelet monotherapy, and aspirin or clopidogrel combined with cilostazole may be prescribed for added protection in high-risk patients. In this paper, we review the development of DAPT from a historical perspective and describe the findings from major clinical trials published up until the end of 2023. Using the 2021 American Heart Association guideline for secondary stroke prevention as a basis for our recommendations, we further discuss areas of controversy and more recent developments to provide an updated review for clinicians to consider in their daily practice.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2024) conducted a review in Ischemic stroke and transient ischemic attack. Dual antiplatelet therapy vs. Antiplatelet monotherapy was evaluated. Dual antiplatelet therapy improves efficacy over antiplatelet monotherapy for the acute management and long-term secondary prevention of non-cardioembolic ischemic stroke and transient ischemic attack.
Synapse has enriched 10 related papers. Consider them for comparative context: